Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 32
- Uncategorized
Public Health, Pilot Projects and Politics: Mapping Adult-Use Cannabis in Europe
We have delved into some of the key data and insights set to be integrated into the new site, providing a taste of what readers can expect. For further exclusive analysis into the European cannabis market, pre-orders for data packages are available now.
- Uncategorized
The Business of Cannabis Awards 2025: Call for Entries Now Open
We are pleased to announce that entries are now open for the Business of Cannabis Awards 2025 — the leading event recognising excellence across Europe’s cannabis sector.
- Uncategorized
Full-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).
- Hemp Industry
High Court Steps in to Arizona ‘Consumable Hemp’ Battle, Offering Hope to Industry
Arizona’s hemp industry this week received a welcome reprieve from an overnight ban on all ‘consumable hemp products’, as the Court of Appeals agreed to consider a collaborative pushback from the industry.
- Uncategorized
Cannabis Rescheduling Given Fresh Hope as DEA Nominee Pledges to ‘Look at Science and Listen to Experts’
Cannabis rescheduling was thrown back into the spotlight last week as the new potential head of the Drug Enforcement Administration (DEA) said it would be a ‘priority’.
- Data & Analysis
The ‘Glaring Omission’ of the Endocannabinoid System From Mainstream Medical Knowledge, And its Real World Impact
Despite being one of the most important regulatory systems in human physiology, the endocannabinoid system (ECS) remains inexplicably absent from almost all mainstream medical education.
- Uncategorized
Can You Trust a Review? Patient Feedback in the Medical Cannabis Sector
As the medical cannabis sector matures, patient feedback is playing an increasingly important role in shaping market dynamics and building trust when it comes to choosing the right clinic.
- Uncategorized
Arizona Moves Ahead With Intoxicating Hemp Ban, Retailers Now Face $20k Fines Per Product
Intoxicating hemp product sellers in Arizona could now face criminal charges, raids and fines as a Country Court Judge ruled to dismiss a temporary restraining order from industry representatives.
- Medical
Tariff Crisis: Israel’s Cannabis Industry Torn in Two as 165% Import Tax Hangs in the Balance
Israel’s cannabis industry is engaged in a heated and divisive showdown as a proposed 165% tax on Canadian cannabis imports, on which a large portion of the industry and many patients rely, hangs in the balance.
- Uncategorized
Tilray & Flora Growth Target Stock Consolidation as Values Continue Decline, Chill Brands Raises £1m From Major Shareholder
Tilray [stock_market_widget type=”chart” template=”line” assets=”TLRY” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The international cannabis giant has announced plans to issue a ‘reverse stock split’, an increasingly common tool in the cannabis industry to artificially inflate stock prices.
- Uncategorized
Legal Challenge Over DEA’s Handling of Cannabis Rescheduling Dropped, Removing 1 Barrier Preventing Progress
A coalition of pro-cannabis medical professionals has dropped its lawsuit against the Drug Enforcement Administration (DEA), clearing one of the many hurdles preventing the process from progressing.
- Uncategorized
Two Federal Cannabis Reform Bills Set to Transform Regulation Across US Introduced
Two separate bipartisan cannabis reform bills that, if passed, would transform US cannabis regulation across the country.
